Hi Itsa, my understanding is that safety and efficacy results can be defined at best January-February 2024, which could be on time or could be a month or two late if unforeseen circumstances arise.
Regarding Trials, it is worth noting that "The Company is able to leverage preparatory work undertaken for the Pase 2b/3 trial including trial site and clinical investigation, selection and relationship development, clinical trial protocols and applications."
For General Information, page-1097
-
- There are more pages in this discussion • 2,448 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.8¢ |
Change
-0.001(1.27%) |
Mkt cap ! $80.86M | |||
| Open | High | Low | Value | Volume |
| 8.0¢ | 8.0¢ | 7.7¢ | $374.4K | 4.803M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 308385 | 7.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.0¢ | 818650 | 4 |
View Market Depth
| Last trade - 16.10pm 04/11/2024 (20 minute delay) ? |
| PER (ASX) Chart |